RedditBluesky
  • Home
  • Artificial Intelligence
  • Cryptocurrencies
  • Technology
  • Gold
  • Stocks
Home » News » Big step on the way to booster vaccinations

Big step on the way to booster vaccinations

Fauci expects USA data on COVID-19 boosters from J&J and Moderna in a few weeks

Ibrahim Al-TarikOctober 5, 2026



The data needed to determine the advisability of booster vaccines for COVID-19 vaccines from Moderna (NASDAQ: MRNA) Inc and Johnson & Johnson (NYSE: JNJ) is expected in a few weeks, the senior medical advisor said by US President Joe Biden on Sunday as officials signaled they expect booster vaccinations to be recommended for a broad mass of Americans. US health officials have already started testing a third dose of Pfizer / BioNTech's vaccine. An advisory panel to the U.S. Food and Drug Administration on Friday recommended a third dose of Pfizer / BioNTech's dual vaccine for people 65 years of age or at high risk for serious COVID-19 illness, but declined a booster for the general population away. Individuals who have received the Moderna vaccine in two doses or the J&J vaccine in one dose are still waiting for a recommendation for possible booster vaccinations. "The actual data we will get for the third vaccination for Moderna and the second vaccination for J&J are literally a few weeks away," said Anthony Fauci, US government's lead infectious disease advisor and advisor to Biden in the NBC show "Meet the Press". "We are working on submitting the data to the FDA so they can review it and make a decision about booster vaccinations for these people," added Fauci. More data could also show that booster vaccinations are needed for the entire US population, Fauci said. The United States ranks at the top of COVID-19 cases and deaths worldwide. Nearly 676,000 people died in the United States during the pandemic, figures compiled by Reuters show. The surge in cases and deaths in the United States in recent months has been greatest in areas with lower vaccination rates, despite health officials begging vaccinators to get vaccinated. The FDA advisors declined to recommend a third dose of Pfizer / BioNTech's vaccine for people 16 years of age and older who had received their second vaccination at least six months previously. While the FDA is not bound by the panel's recommendation, it will consider it in its decision on whether to recommend a third vaccination. "This is not the end of the story," Fauci said on CNN's State of the Union. "They will continue to look at this, literally in real time," added Fauci. Biden announced in August the government's intention to introduce booster vaccinations for people 16 years and older, pending approval by the FDA and the experts at the Centers for Disease Control and Prevention. The FDA's decision-making process does not nullify the White House's position in favor of booster vaccinations, Fauci said. Fauci urged that people who do not belong to the group that the FDA panel recommended booster vaccination should wait pending formal approval to vaccinate. Francis Collins, Director of the U.S. National Institutes of Health, said on Fox News Sunday that he expected "it will become clear in the next few weeks that booster vaccination may need to be expanded," citing existing data from the United States and Israel, which indicate that the vaccine is becoming less effective over time.

Booster USAModernaJohnson & JohnsonPfizer





Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.


Claw and Order: Antimony Rules the Resource Realm
Read Next

Claw and Order: Antimony Rules the Resource Realm

  • RIDE THE BULL

    Your Front Row Seat to the Stories That Move Markets. – Subscribe Now to our Newsletter!

  • Trending Now

    • Mark Carney Single-Outs NexGen's Rook 1 as a Critical Project of National Interest
      Mark Carney Single-Outs NexGen's Rook 1 as a Critical Project of National Interest
    • Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
      Skyharbour Resources Advances Nasdaq Aspirations with Fresh Athabasca NI 43-101 Filings
    • Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
      Amazon Inks 20-Year Deal with Constellation to Expand Clean Nuclear Capacity
    • Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama
      Four for Four: Super Copper Logs Visible Copper at El Alto Target in Atacama

Claim Your Spot with Juniorstocks.com

Unlock the stories that move markets directly in your inbox


ContactDisclaimerData PrivacyTerms of Use
  • Bluesky
  • Reddit
Copyright 2026 ©Juniorstocks.com - All Rights Reserved.